Vertaling van "sustained release " (Frans → Nederlands) :

TERMINOLOGIE

Hypersécrétion du pancréas endocrine de:polypeptide:intestinal vaso-actif | pancréatique | releasing factor de l'hormone de croissance | somatostatine
verhoogde secretie vanuit endocriene pancreas van | groeihormoon-releasing hormoon [GH-RH] | verhoogde secretie vanuit endocriene pancreas van | pancreaspolypeptide [PP] | verhoogde secretie vanuit endocriene pancreas van | somatostatine | verhoogde secretie vanuit endocriene pancreas van | vasoactive-intestinal polypeptide [VIP]

IN-CONTEXT TRANSLATIONS

L’innocuité et l’efficacité de Decapeptyl Sustained Release 22,5 mg n’ont pas été établies chez le nouveau-né, le nourrisson, l’enfant et l’adolescent, c’est pourquoi Decapeptyl Sustained Release 22,5 mg n’est pas indiqué dans ces populations.
De veiligheid en werkzaamheid van Decapeptyl Sustained Release 22,5 mg werden niet onderzocht bij pasgeborenen, zuigelingen, kinderen en adolescenten. Decapeptyl Sustained Release 22,5 mg is daarom niet aangewezen voor gebruik bij deze groepen.

13. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained release Bupropion, a nicotine patch or both for smoking cessation.
13. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained release bupropion, a nicotine patch or both for smoking cessation.

12. Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, Johnston JA, et al. Lateterm smoking cessation despite initial failure: an evaluation of Bupropion sustained release, nicotine patch, combination therapy, and placebo.
12. Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, Johnston JA, et al. Lateterm smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo.

Abernethy A, Currow D, Frith P et al. Randomised, double blind, placebo controlled crossover trial of sustained release
Abernethy A, Currow D, Frith P et al. Randomised, double blind, placebo controlled crossover trial of sustained

L. Allan et al. : Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.
L. Allan et al.: Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.

A prospective safety surveillance study for Bupropion sustained-release in the treatment of depression.
A prospective safety surveillance study for bupropion sustained-release in the treatment of depression.

39. Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA et al. Effects of sustained-release Bupropion among persons interested in reducing but not quitting smoking.
39. Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA et al. Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking.

Decapeptyl Sustained Release 3,75 mg poudre et solvant pour suspension injectable.
Decapeptyl Sustained Release 3,75 mg poeder en oplosmiddel voor suspensie voor injectie.

Les effets indésirables suivants peuvent survenir en cas d’un traitement avec d’autres formes de Decapeptyl: En début du traitement avec Decapeptyl SR (Sustained Release) 3,75 mg et 11,25 mg: saignements menstruels irréguliers pendant le premier mois du traitement.
Volgende bijwerkingen kunnen voorkomen bij de behandeling met andere vormen van Decapeptyl: Bij de start van de behandeling met Decapeptyl SR (Sustained Release) 3,75 mg en 11,25 mg: onregelmatige menstruatiebloeding tijdens de eerste maand van de behandeling.

40. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S et al. Effectiveness of Bupropion sustained release for smoking cessation in a health care setting: a randomized trial.
40. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial.